EP
RPRX icon

Edgestream Partners’s Royalty Pharma RPRX Stock Holding History

Edgestream Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Sell
6,747
-60,195
-90% -$3.13M 0.01% 837
2026
Q1 		$3.21M Sell
66,942
-37,986
-36% -$1.66M 0.11% 366
2025
Q4 		$4.05M Buy
104,928
+3,968
+4% +$151K 0.11% 326
2025
Q3 		$3.56M Buy
+100,960
New +$3.65M 0.1% 370
2025
Q2 		– Sell
-21,158
Closed -$659K – 1036
2025
Q1 		$659K Buy
+21,158
New +$671K 0.02% 667

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgestream Partners's RPRX Position: Q2 2026 in Review

Edgestream Partners reduced its Royalty Pharma (RPRX) stake by 90% in Q2 2026, selling an estimated $3.13M and leaving 6,747 shares worth $378K. The position accounts for 0.01% of the portfolio, ranked #837.

Edgestream Partners first reported a position in RPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.05M in Q4 2025. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Edgestream Partners held 6,747 shares of Royalty Pharma worth $378K as of Q2 2026.
  • Edgestream Partners sold 60,195 Royalty Pharma shares in Q2 2026, an estimated $3.13M.
  • Royalty Pharma made up 0.01% of Edgestream Partners's portfolio in Q2 2026, its #837 holding.
  • Edgestream Partners first reported a position in Royalty Pharma in Q1 2025 and has held it in 5 quarters since.
  • Edgestream Partners's Royalty Pharma position peaked at $4.05M in Q4 2025.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.